Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome ...
(PR-inside.com) Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jagu…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


